We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
This episode covers one of the most sought after and critical fields of pharmaceutical research, cell and gene therapy. Our guest, the CEO and сo-founder of NKILT Therapeutics, Raphaël Ognar, describes a cutting-edge cell therapy biotech that is developing a novel approach to directly targeting leukemia.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
